Loading…
← CockpitCompetitor Analysis › 688278.SS Xiamen Amoytop Biotech Co., Ltd. Class AOpen in the cockpit ↗

Xiamen Amoytop Biotech Co., Ltd. Class A688278.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Chinese biopharma specializing in recombinant protein drugs, notably long-acting pegylated interferon.

≈ A small, interferon-focused Chinese biologics makerMomentum weak 27
Mkt cap
$2.56B
US dollars, full cap
Free float
41%
of shares outstanding
$/day
$17.1M
20-day average traded
Fwd P/E
15.0×
forward earnings
ROIC−WACC
+22.7 pp
WACC 5.3%
Hurdle
-37 pp
Req g minus delivered
Next earnings
128 days
26 Mar 2027
Close · CNYCN¥42.14
1D-1.8%
1W-3.1%
1M-9.5%
3M-31.4%
6M-27.1%
YTD-49.6%
1Y-42.5%
ATR %4.0%
52w lowhigh50.8% off high

What Xiamen Amoytop Biotech does

Chinese biopharma specializing in recombinant protein drugs, notably long-acting pegylated interferon.

Sells its long-acting interferon mainly to hospitals through distributors, so sales rest on one product family, and hospital tenders and inclusion on China's insurance reimbursement lists set price and volume. Competing imported and domestic long-acting interferons keep price pressure on it.

In one line: A small, interferon-focused Chinese biologics maker.

Products and services

  • Pegylated interferon
  • Recombinant human proteins

Customers

  • Hospitals
  • Hepatitis/oncology specialists

Where it sits in the supply chain

  • Health Care
  • Biopharmaceuticals
  • Recombinant proteins

What could go right

  • Import substitution for biologics
  • Hepatitis/oncology treatment demand

What could go wrong

  • Narrow product concentration
  • Pricing pressure via procurement

Moat: narrow (IP / patents, regulatory licence). One of few domestic makers of long-acting pegylated interferon, reducing reliance on imports.

Headquarters: Xiamen, China · Employees: 3,644

Named competitors

Xiamen Amoytop Biotech at a glance

Size Xiamen Amoytop Biotech (688278.SS) is a China Health Care company (Biotechnology) with a market value of $2.56B, the 928th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥42.14 on 18 Nov 2026.

Performance Over six months the shares fell 27.1%, against -2.0% for the median peer and -20.0% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.

Growth Revenue grew 18.3% over the last twelve months (peer median +9.4%); the operating margin is 26.7% (peer median -22.7%).

Valuation It trades at 15.0× forward earnings against a peer median of 36.4× (cheapest of 7).

Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +36%, so the hurdle is -37 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 22.7 points above its cost of capital (5.3% WACC).

Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 98688278.SS 73
Six months, rebased to 100: Xiamen Amoytop Biotech against the median of its 20 peers (local-currency closes).

Xiamen Amoytop Biotech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.95BCN¥3.68BCN¥2.81BCN¥2.09BCN¥1.52B
Revenue growth—+31%+34%+38%—
Gross profitCN¥3.64BCN¥3.37BCN¥2.61BCN¥1.94BCN¥1.34B
EBITDAn/aCN¥1.36BCN¥1.02BCN¥728MCN¥410M
Net incomeCN¥842MCN¥1.03BCN¥828MCN¥555MCN¥287M
Free cash flowCN¥260MCN¥473MCN¥179MCN¥224MCN¥144M
Capital expenditureCN¥307MCN¥256MCN¥251MCN¥288MCN¥219M
Total debtCN¥2.20BCN¥176MCN¥8.94MCN¥7.92MCN¥9.74M

Quarterly statements and history in the cockpit →

Xiamen Amoytop Biotech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%XNCR300142MBX02830068879688300255BAVA2228RCUSLKFTVIMIAN302440RUBICONDNLIPHVSTLXADMABEAM688278.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Xiamen Amoytop Biotech is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%0×100×200×300×300142BAVAVIMIANRUBICONTLXADMA688278.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Xiamen Amoytop Biotech is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%300142BAVAVIMIANADMA688278.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Xiamen Amoytop Biotech is the large dot.

Xiamen Amoytop Biotech competitors and peer comparison

Head to head with its named competitors (688278.SS vs 688520.SS vs RO.SW)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Xiamen Amoytop Biotech 688278.SS$2.56B-27%+18%27%15.0×-0.6%
Sinocelltech 688520.SS$1.90B-35%-40%-75%n/an/a
Roche RO.SW$381B+21%-1%31%19.9×1.7%

How Xiamen Amoytop Biotech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Xiamen Amoytop Biotech against its 20 peers (data as of 18 Nov 2026)
Measure688278.SSPeer medianRank in peer set
1-month return-9.5%-2.6%8th lowest of 21
6-month return-27.1%-2.0%5th lowest of 21
Distance from 52-week high-50.8%-30.1%4th lowest of 21
Revenue growth (TTM)+18.3%+9.4%8th highest of 17
Operating margin26.7%-22.7%3rd highest of 18
Forward P/E15.0×36.4×cheapest of 7
Growth the price implies (Req g, 7 yrs)-0.6%6.3%3rd least demanding of 5
Growth delivered (Del g)+36.0%+35.9%3rd highest of 5
Hurdle (Req g minus delivered)-36.6 pp-31.4 pp2nd least demanding of 5
ROIC minus cost of capital+22.7 pp-9.4 pp3rd highest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Xiamen Amoytop Biotech 688278.SSChina$2.56B-27%+18%27%15.0×-0.6%+36.0%
Xencor XNCRUnited States$2.58B+204%+34%-73%n/an/an/a
Walvax Biotechnology 300142.SZChina$2.48B-26%-23%5%348.7×29.5%-3.8%
MBX Biosciences MBXUnited States$2.65B+70%n/an/an/an/an/a
HLB 028300.KSSouth Korea$2.69B-49%+26%-96%n/an/an/a
Sunshine Lake Pharma 6887.HKHong Kong$2.72B-7%+20%-3%n/an/an/a
Zai Lab 9688.HKHong Kong$2.79B+23%0%-63%n/an/an/a
Hebei Changshan Biochemical Pharmaceutical 300255.SZChina$2.33B-59%0%-25%n/an/an/a
Bavarian Nordic A/S BAVA.CODenmark$2.82B+23%-8%18%16.6×-4.3%+27.4%
XtalPi 2228.HKHong Kong$2.87B-34%+4%-127%n/an/an/a
Arcus Biosciences RCUSUnited States$2.27B-34%-58%-475%n/an/an/a
Lakefront Biotherapeutics LKFT.ASNetherlands$2.26B+31%+223%64%n/an/an/a
Vimian VIMIAN.STSweden$2.26B+51%+8%19%38.4×13.4%+44.5%
SKBS 302440.KSSouth Korea$2.25B-12%+11%-23%n/an/an/a
Rubicon Research RUBICON.NSIndia$2.94B+68%+37%21%66.6×n/an/a
Denali Therapeutics DNLIUnited States$2.95B-2%n/a-2,488%n/an/an/a
Pharvaris PHVSUnited States$2.21B+7%n/an/an/an/an/a
Dyne Therapeutics DYNUnited States$2.97B-10%n/an/an/an/an/a
Telix Pharmaceuticals TLX.AXAustralia$2.99B-2%+27%-1%34.5×n/an/a
ADMA Biologics ADMAUnited States$3.01B+58%+6%45%16.7×-0.8%+64.6%
Beam Therapeutics BEAMUnited States$2.17B-22%+163%-268%n/an/an/a

Questions

Who are Xiamen Amoytop Biotech's main competitors?
Named competitors: Sinocelltech Group (688520.SS), Roche (RO.SW). The cockpit's measured peer set (industry) also includes Xencor (XNCR), Walvax Biotechnology (300142.SZ), MBX Biosciences (MBX), HLB (028300.KS), Sunshine Lake Pharma (6887.HK), Zai Lab (9688.HK).
Is Xiamen Amoytop Biotech expensive compared with its peers?
On forward p/e it trades at 15.0× against a peer median of 36.4×, cheapest of 7 in its peer set. For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +36%, so the hurdle is -37 pp: the price already allows for a slowdown.
How has Xiamen Amoytop Biotech stock performed?
Over six months to 18 Nov 2026 the shares returned -27.1% against -2.0% for the median peer; over one year -42.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.